Logo image of CBIO

CRESCENT BIOPHARMA INC (CBIO) Stock Fundamental Analysis

NASDAQ:CBIO - Nasdaq - US38000Q1022 - Common Stock - Currency: USD

13.02  -0.12 (-0.91%)

Fundamental Rating

1

CBIO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. The financial health of CBIO is average, but there are quite some concerns on its profitability. CBIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CBIO has reported negative net income.
CBIO had a negative operating cash flow in the past year.
In the past 5 years CBIO always reported negative net income.
CBIO had a negative operating cash flow in each of the past 5 years.
CBIO Yearly Net Income VS EBIT VS OCF VS FCFCBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -341.52%, CBIO is not doing good in the industry: 93.73% of the companies in the same industry are doing better.
The Return On Equity of CBIO (-712.87%) is worse than 80.82% of its industry peers.
Industry RankSector Rank
ROA -341.52%
ROE -712.87%
ROIC N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
CBIO Yearly ROA, ROE, ROICCBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

CBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBIO Yearly Profit, Operating, Gross MarginsCBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

5

2. Health

2.1 Basic Checks

CBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CBIO has about the same amount of shares outstanding.
The number of shares outstanding for CBIO has been increased compared to 5 years ago.
There is no outstanding debt for CBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CBIO Yearly Shares OutstandingCBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CBIO Yearly Total Debt VS Total AssetsCBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CBIO has an Altman-Z score of -52.54. This is a bad value and indicates that CBIO is not financially healthy and even has some risk of bankruptcy.
CBIO has a Altman-Z score of -52.54. This is amonst the worse of the industry: CBIO underperforms 93.19% of its industry peers.
There is no outstanding debt for CBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -52.54
ROIC/WACCN/A
WACC9.7%
CBIO Yearly LT Debt VS Equity VS FCFCBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.92 indicates that CBIO should not have too much problems paying its short term obligations.
CBIO's Current ratio of 1.92 is on the low side compared to the rest of the industry. CBIO is outperformed by 76.70% of its industry peers.
A Quick Ratio of 1.92 indicates that CBIO should not have too much problems paying its short term obligations.
The Quick ratio of CBIO (1.92) is worse than 75.45% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
CBIO Yearly Current Assets VS Current LiabilitesCBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

CBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.09%, which is quite impressive.
Looking at the last year, CBIO shows a very negative growth in Revenue. The Revenue has decreased by -87.50% in the last year.
CBIO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -90.05% yearly.
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2252.94%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -54.50% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.84%
EPS Next 2Y-145.42%
EPS Next 3Y-83.5%
EPS Next 5Y-54.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CBIO Yearly Revenue VS EstimatesCBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2020 2021 2022 2023 5M 10M 15M 20M
CBIO Yearly EPS VS EstimatesCBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CBIO. In the last year negative earnings were reported.
Also next year CBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBIO Price Earnings VS Forward Price EarningsCBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBIO Per share dataCBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

CBIO's earnings are expected to decrease with -83.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-145.42%
EPS Next 3Y-83.5%

More info and screens

0

5. Dividend

5.1 Amount

CBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRESCENT BIOPHARMA INC

NASDAQ:CBIO (7/17/2025, 4:30:02 PM)

13.02

-0.12 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-06 2025-08-06
Inst Owners47.7%
Inst Owner Change0%
Ins Owners1.41%
Ins Owner Change132.58%
Market Cap180.85M
Analysts84
Price TargetN/A
Short Float %N/A
Short Ratio0.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-17025%
EPS NY rev (3m)-17025%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 34.03
P/tB 34.03
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-3.49
Fwd EYN/A
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-2.24
OCFYN/A
SpS0
BVpS0.38
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -341.52%
ROE -712.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z -52.54
F-Score2
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)26.82%
Cap/Depr(5y)22.05%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2252.94%
EPS Next Y-6.84%
EPS Next 2Y-145.42%
EPS Next 3Y-83.5%
EPS Next 5Y-54.5%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.84%
OCF growth 3YN/A
OCF growth 5YN/A